Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b pediatric letermovir study after allogeneic HSCT
2018-001326-25Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by Merck & Co. Primary endpoint: Area under the curve from time 0 to 24 hours post-dose (AUC0-24) of plasma letermovir during intensive PK for oral formulation. Started Feb 2019; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2018-001326-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001326-25.